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Summary
Introduction: Severe acute respiratory syndrome (SARS) caused large outbreaks of
atypical pneumonia in 2003, with the largest localized outbreak occurring in Beijing,
China. Lymphopenia was prominent amongst the laboratory abnormalities reported in
acute SARS.
Methods: The effect of SARS on peripheral blood lymphocytes and their subsets was
examined in 271 SARS coronavirus-infected individuals.
Results: There was a significant decrease in the CD45+, CD3+, CD4+, CD8+, CD19+ and
CD16+/56+ cell counts over the five weeks of the SARS illness although CD4+/CD8+
ratios did not change significantly. The lymphopenia was prolonged, reaching a nadir
during days 7—9 in the second week of illness before returning towards normal after
five weeks, with the lowest mean CD4+ cell count of 317 cells  106/L at day 7, and
CD8+ cell count of 239 cells  106/L at day 8. Patients with more severe clinical
illness, or patients who died, had significantly more profound CD4+ and CD8+
lymphopenia.
Discussion: Lymphopenia is a prominent part of SARS-CoV infection and lymphocyte
counts may be useful in predicting the severity and clinical outcomes. Possible reasons
for the SARS-associated lymphopenia may be direct infection of lymphocytes by SARS-* Corresponding author. Tel.: +86 10 82801617; fax: +86 10 82802221.
E-mail address: zhongpinghe@yahoo.com (Z. He).
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Severe acute respiratory syndrome (SARS) is a new
emerging disease that has affected many countries,
with theWorld Health Organization (WHO) reporting
8422 probable cases up to 7 August 2003. There have
been 916 deaths with a reported mortality of
10.9%.1 Most cases have occurred in China (5327
cases), Taiwan, Hong Kong SAR, Singapore and
Canada. The largest localized outbreak worldwide
has been in Beijing, with 2521 cases. Three hundred
and four patients fitting the clinical case definition
of SARS were hospitalized at the Ditan Hospital in
Beijing between 26 March and 31 May 2003.
Most early reports classified cases as SARS on the
basis of clinical case definitions, although the recog-
nition of the SARS-CoV as the causative agent
allowed specific laboratory confirmation to be
made.2—10 Approximately 75% of patients presenting
with SARS have a laboratory-confirmed SARS-CoV
infection,5 with the remainder either having other
infectious causes of severe atypical pneumonia or
undetected SARS-CoV infection. Among the clinical
and laboratory features of SARS, a number of hema-
tological abnormalities have been described. Pro-
minent amongst these is a total lymphopenia,
although in most studies lymphocyte subset analyses
were not reported.4,6,8—11
In this study, an examination of lymphocyte sub-
sets was undertaken in a cohort of 271 laboratory-
confirmed cases of SARS.Methods
The daily clinical and laboratory findings of 304 SARS
patients at the Ditan Hospital in Beijing were
entered on a pre-designed database. The clinical
case definition of probable SARS included a fever of
38 8C or higher, cough or shortness of breath, new
pulmonary infiltrates on chest radiography, and
close contact with a person who is a suspected or
probable case of SARS. Day 1 of illness was defined as
the day of onset of fever. Blood was collected for
SARS-CoV specific antibody testing from all patients
during hospitalization. SARS-CoV specific IgM and
IgG were detected using an indirect immunofluor-
escence assay (IFA, Euroimmun AG, Lubeck, Ger-many), SARS-CoV RNA was detected in throat
washes, stools and blood using a SARS-CoV RNA
fluorescence quantitative RT-PCR assay (ShenZhen
PJ Company, Shenzhen, Guangdong Province,
China). Immunological tests included T, NK and B
lymphocyte cell counts by flow cytometry (MultiT-
EST CD45Percp/CD3FITC/CD4APC/CD8PE TruCount
Four-Color kit, MultiTEST CD45Percp/CD3FITC/
CD16+56PE/CD19APC TruCount Four-Color kit, BD
Biosciences, San Jose, CA, USA). Lymphocyte counts
were performed as controls on 51 non-SARS-
affected and otherwise healthy individuals. All ana-
lyses were performed at a single laboratory. The
study was approved by the Ethics Committee of
Ditan Hospital, Beijing, China.
Patients satisfying the case definition of probable
SARS were retrospectively classified after discharge
into non-severe (122) and severe (149) cases. The
non-severe and severe groups were defined accord-
ing to ‘The standard of clinical diagnosis for atypical
pneumonia’ guidelines listed by the Chinese Public
Health Ministry on 4 May 2003. The patients in the
non-severe group had a fever of 38 8C or higher, a
cough or shortness of breath, and new pulmonary
infiltrates on chest radiography. The patients in the
severe group had in addition at least one of the
following features: dyspnea (respiratory rate >30/
minute), hypoxemia (PaO2 <70 mmHg or SpO2 <93%
whilst on oxygen at a rate of 3—5 L/minute), acute
lung injury/acute respiratory distress syndrome, a
chest radiograph showing multifocal involvement
over one third of the lung fields (or that developed
to 50% in 48 hours), and shock or multiple organ
dysfunction syndrome (MODS). They also had other
underlying diseases, developed a secondary infec-
tion or were over 50 years old. Patients satisfying
the case definition of probable SARS were retro-
spectively classified after discharge into those who
recovered (246 cases) and those who died from SARS
(25).Results
Probable SARS patients were regarded as laboratory
confirmed if they had at least one of the following:
SARS-CoV IgG and/or IgM antibody detected by IFA
three or more weeks after the onset of the illness,CoV, lymphocyte sequestration in the lung or cytokine-mediated lymphocyte traffick-
ing. There may also be immune-mediated lymphocyte destruction, bone marrow or
thymus suppression, or apoptosis.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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.and/or SARS-CoV RNA detected by RT-PCR during the
first two weeks of illness.
In this study, 271/304 (89.1%) patients were
laboratory confirmed as having SARS, including
148 (55%) with SARS-CoV detected by RT-PCR on
respiratory tract or fecal samples. Of the 148
SARS-CoV RT-PCR positive samples, SARS-CoV IgG
was detected in 145 (98%) and SARS-CoV IgM in
117 (79%) using IFA.12 There were 33/304 (10.9%)
that were negative on SARS testing. An alternative
laboratory diagnosis was made in 27/33, of which
the most common were acute influenza B (13 cases)
and Klebsiella pneumoniae infection (nine cases).
The mean age of the 271 laboratory-confirmed SARS
cases was 36  16 years, with 51 (18.8%) over 50
years of age and nine (3.3%) under 18 years. There
were 157 (57.9%) females and 114 (42.1%) males.
There were 92 (33.9%) health care workers, includ-
ing 51 nurses, 30 physicians and 11 others in the
cohort. Thirty-two patients had underlying health
problems, including diabetes (18 cases), cardiac
disease (eight cases), malignancy (four cases),
chronic airways disease (one case) and chronic renal
failure (one case). One hundred and twelve indivi-
duals (41.3%) acquired SARS in the hospital setting
as health care workers, inpatients, or visitors,
mostly in the wards of the hospital. A further 62
cases were infected following home exposure, when
family members or friends of hospital-associated
cases had come into close contact with affected
individuals.
Lymphocyte subsets
The lymphocyte subpopulation counts were com-
pared between 696 samples collected from 271
cases of laboratory-confirmed SARS patients and
51 controls (Table 1). The total lymphocyte counts
from SARS patients were compared with those from
normal individuals, and the lymphocyte counts at
each week after the onset of the illness were com-
pared with other weeks of illness and with those
from normal individuals. Using nonparametric tests
there were significant decreases in the CD45+,
CD3+, CD4+, CD8+, CD19+ and CD16/56+ counts over
each of the five weeks of the SARS illness compared
to healthy controls, although the CD4+/CD8+ ratio
did not change significantly over the course of the
illness. The various lymphocyte populations (CD45+,
CD3+, CD4+ and CD8+) were below the normal
ranges in the first week of the clinical illness, reach-
ing a nadir during the second week before returning
towards normal levels. There were significant dif-
ferences in lymphocyte subset counts between
weeks 1 and 2, weeks 2 and 3, weeks 4 and 5,
and weeks 1 and 5 (Table 1) (Figures 1—3).
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Figure 1 Kinetics of CD45+, CD4+, CD8+, CD3+, CD19+
and CD16+56+ lymphocyte subsets (expressed as mean
number of cells  106/L) measured over the first five
weeks of illness in laboratory-confirmed SARS patients
and in otherwise healthy controls.
Figure 2 Kinetics of CD45+, CD19+, CD16+56+ lympho-
cytes (expressed as mean number of cells x 106/L) mea-
sured over the first 21 days of illness in laboratory-
confirmed SARS patients and in otherwise healthy con-
trols.
Table 2 Kinetics of CD45+, CD3+, CD4+, CD8+, CD19+ and CD16/56+ counts (expressed as cells  106/L 1 standard
deviation) in SARS patients during the first 21 days of illness.
Day after onset Cases CD45+ CD3+ CD4+ CD8+ CD19+ CD16/56+
No. SD No. SD No. SD No. SD No. SD No. SD
1 14 1108  694 810  525 496  357 309  198 172  109 117  65
2 13 1000  525 668  400 367  245 293  211 163  174 131  57
3 25 1111  528 767  394 412  202 317  186 188  164 174  105
4 29 1174  521 777  376 457  287 314  120 148  78 232  159
5 33 1181  666 779  477 446  333 299  163 196  108 163  103
6 40 1006  487 651  369 349  217 285  162 160  85 162  108
7 28 973  495 603  329 317  185 275  168 185  118 133  97
8 40 949  393 582  268 323  190 239  105 182  107 155  150
9 39 950  564 606  449 322  256 276  253 177  107 146  152
10 41 964  589 643  507 348  284 282  237 213  145 126  87
11 54 969  669 632  484 356  293 252  187 204  160 111  95
12 38 920  555 593  423 330  266 258  215 220  185 96  63
13 36 983  500 655  391 385  249 251  141 196  126 108  76
14 31 1126  909 745  706 437  435 319  294 243  175 106  108
15 39 1187  764 782  516 440  322 318  208 263  235 107  88
16 33 1227  836 854  629 485  366 361  298 228  121 134  194
17 28 1244  635 854  478 514  330 315  172 259  146 130  121
18 35 1621  990 1178  744 662  407 459  323 284  188 139  138
19 32 1440  667 1053  551 603  345 443  264 240  126 110  86
20 26 1365  875 958  691 526  423 366  252 301  212 113  101
21 27 1521  1057 1063  732 622  436 416  345 315  253 115  135
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Figure 3 Kinetics of lymphocyte subsets (expressed as mean number of cells  106/L) measured over the first five
weeks of illness in non-severe and severe laboratory-confirmed SARS patients, and in otherwise healthy controls.These observations are further defined in Table 2
where the CD45+, CD3+, CD4+, CD8+, CD19+ and
CD16/56+ counts on samples collected daily during
the first 21 days of SARS are listed. The total, CD4+
and CD8+ lymphopenia wasmost marked at days 7—9
in the second week of the illness. In Table 3 the
lymphocyte subpopulation counts were compared
between those with severe SARS (260 samples from
149 patients), non-severe SARS (436 samples from
122 patients), and those that recovered (613 sam-
ples from 246 cases) or died (48 samples from 25
patients) from SARS. The CD45+, CD3+, CD4+, CD8+,CD19+ and CD16/56+ counts were significantly lower
(using nonparametric tests) in those patients that
died compared to those who recovered, and in those
with severe disease compared to those with non-
severe disease.Discussion
The interaction between the SARS-CoV and the
immune system is complex. In this study, lympho-
cyte subsets were measured over five weeks in 271
328 Z. He et al.
Table 3 Lymphocyte subpopulation counts in severe and non-severe SARS cases, and in patients who recovered or
died of SARS.
Lymphocytes Groups 1st week 2nd week 3rd week 4th week 5th week
NS = 91, S = 35 NS = 118, S = 68 NS = 101, S = 62 NS = 66, S = 45 NS = 60, S = 50
R = 113, D = 8 R = 158, D = 19 R = 144, D = 11 R = 98, D = 6 R = 100, D = 4
CD45+ Non-severe (NS) 1104  5201 1123  6271 1550  8231 1624  8281 1922  9111
Severe (S) 936  478 723  366 1162  805 1247  897 1493  791
Recovery (R) 1100  5183 1039  5933 1462  7933 1542  8573 1802  8623
Death (D) 609  201 552  285 742  892 481  470 437  237
CD3+ Non-severe 737  3731 752  5141 1101  6001 1189  6461 1439  6881
Severe 591  350 447  280 805  621 860  669 1052  586
Recovery 726  3753 688  4823 1033  5983 1115  6643 1324  6523
Death 394  193 310  178 521  693 303  264 283  181
CD4+ Non-severe 418  2611 419  3031 635  3611 661  3531 843  4851
Severe 303  167 257  179 463  373 493  432 601  374
Recovery 401  2483 386  2853 596  3653 627  3903 771  4503
Death 223  124 170  104 276  340 185  153 160  111
CD8+ Non-severe 299  1381 319  2441 429  2641 494  3341 532  2841
Severe 269  188 185  118 325  268 347  301 425  252
Recovery 302  1553 291  2263 406  2603 462  3293 505  2683
Death 168  98 133  88 195  216 119  115 116  67
CD4+/CD8+ Non-severe 1.42  0.592 1.39  0.611 1.61  0.712 1.54  0.652 1.66  0.702
Severe 1.42  1.00 1.61  1.09 1.53  0.77 1.50  0.67 1.52  0.60
Recovery 1.39  0.584 1.44  0.744 1.59  1.704 1.52  0.684 1.62  0.684
Death 1.85  1.85 1.73  1.40 1.41  1.05 1.72  0.49 1.32  0.19
CD19+ Non-severe 171  1012 228  1731 297  2092 286  2252 316  2552
Severe 167  118 164  94 226  138 226  164 300  206
Recovery 175  1073 216  1573 283  1873 291  2193 291  2193
Death 114  62 107  54 159  173 170  211 170  211
CD16/56+ Non-severe 167  1132 127  991 129  1182 129  992 144  1082
Severe 167  113 93  69 113  155 98  83 129  125
Recovery 172  1153 117  923 130  1383 131  1053 131  1053
Death 93  47 97  84 45  35 54  91 54  91
NS = non-severe cases; S = severe cases; R = recovered cases; D = cases that died. Counts expressed as cells  106/L 1 standard
deviation. Comparison of lymphocyte counts between the severe and non-severe SARS cases at each week (1—5) of illness: 1p < 0.05,
2p > 0.05. Comparison of lymphocyte counts between cases who died and those cases who survived at each week (1—5) of illness:
3p < 0.01, 4p > 0.05.laboratory-proven non-severe and severe cases of
SARS, where patients either recovered or died. Total
lymphocyte counts decreased in the first two weeks
of illness (the nadir was in week 2) before increasing
in the third week and returning to normal levels by
the fifth week. Peripheral blood lymphocyte subsets
(CD45+, CD3+, CD4+, CD8+) were quantitated by
dynamic methods in a large cohort of 271 labora-
tory-proven cases of SARS.
This study confirms observations of lymphopenia
noted in most other series of SARS cases. 4,6,8—11 A
study in Hong Kong reported an absolute lympho-
penia (<1000  106/L) in 98% of patients during
the course of their illness, most marked in the
second week.11 The data discussed here extend
these observations (and provide the first data from
mainland China), showing that the total lympho-
cyte counts of SARS patients were lower than those
of normal individuals throughout the clinical
course, and that this was more marked in severedisease compared to less severe illness, and in
those who died compared to the survivors. A
study of 75 patients from the Amoy Gardens out-
break in Hong Kong did not find an association of
total lymphocyte counts and progression to venti-
latory support and intensive care,10 although there
are differences in the progression to acute respira-
tory distress syndrome (ARDS), oxygen saturation
and gastrointestinal symptoms in these two
cohorts. However, an association of lymphopenia
with more severe disease was seen in another
cohort of SARS cases from Hong Kong.6 In contrast
with other series of adult SARS cases, in the
study reported here all patients had laboratory
evidence of SARS-CoV infection. In two series
totalling 25 children with probable or suspect
SARS (although only four children had labora-
tory-proven SARS), total lymphopenia was common
and more prominent in older children with more
severe disease.13,14
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CD16/56+) were also counted in all patients. A
significant CD4+ and CD8+ T cell lymphopenia has
been observed in the first two weeks of the SARS
illness in 31 patients,11 but in this study, a more
prolonged CD4+ and CD8+ lymphopenia was noted.
CD4+ and CD8+ cells fell by approximately one half
in the second week of the illness before returning to
near normal by the end of week 5. In addition,
patients with more severe disease had lower counts
that took longer to rise. The data show that the
CD4+ and CD8+ counts were lower in more severely
ill patients and in those that died. The CD4+/CD8+
ratios were not significantly different in the various
patient groups. CD19+ B lymphocytes were the first
lymphocytes to numerically recover after two weeks
and their recovery was associated with the appear-
ance of SARS-CoV specific IgG and IgM. CD16/56+ NK
cells also began to decrease in the first week
(although there was a rise in NK cells towards the
end of week 1) to their lowest levels during week 4,
and had not returned to normal by week 5.
Lymphopenia is a prominent part of SARS-CoV
infection and lymphocyte counts may be useful in
predicting the severity and clinical outcomes. Total
and subset lymphopenia occurs in other acute (e.g.
measles, cytomegalovirus) and chronic (e.g. HIV)
viral infections in humans and animals, but lympho-
penia has not been a feature of other human cor-
onavirus infections in adults.15—17 Lymphopenia has
been described in some cases of experimental cor-
onavirus 229E infections in humans.18 A possible
reason for the lymphopenia may be that lympho-
cytes are directly infected and destroyed by SARS-
CoV. However, angiotensin-converting enzyme 2 has
been identified as a functional cellular receptor for
the SARS-CoV, a protein that is not expressed on B or
T lymphocytes.19,20 This would suggest that direct
viral invasion and destruction of lymphocytes is not
a major cause of the acute lymphopenia in SARS, but
this requires further study.
Other possible explanations for the lymphopenia
are lymphocyte sequestration in the lung where
SARS-CoV damage is most evident, or cytokine-
mediated altered lymphocyte trafficking. There
may be immune-mediated lymphocyte destruction
(lymphocyte depletion has been noted in autopsies
of lymph nodes from SARS cases),21 bone marrow or
thymus suppression, or apoptosis. Apoptosis has
been observed in vitro in measles-induced lympho-
penia,22 and coronavirus 229E can cause in vitro
apoptosis in monocytes/macrophages.23 Whether
different strains of SARS-CoV have variable effects
on immune responses and clinical disease (as occurs
with experimental measles in macaques)24 is
unknown. It is possible that the SARS-CoV-inducedimmune suppression predisposes to secondary infec-
tions, especially in the more severely ill patients,
and it is unknown if there are any longer term
effects on humoral or cell-mediated immunity fol-
lowing SARS.
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